Loading...
ROCO
6564
, Last price  
Name

Enimmune Corp

Chart & performance

D1W1MN
ROCO:6564 chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
—
Shs. 5Y
6.10%
Rev. 5Y
16.07%
Div Yld LY
—
Div Yld TTM
—
Revenues
48m
+20.74%
1,944,00022,876,000109,822,000188,415,00043,494,00039,915,00048,194,000
Net income
-165m
L+4.44%
-56,645,000-74,453,000-47,246,000-247,963,000-223,743,000-157,546,000-164,537,000
CFO
-144m
L-0.18%
-59,923,000-107,420,000-71,550,000-200,636,000-138,133,000-143,776,000-143,513,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East Respiratory Syndrome Coronavirus (MERS-CoV). Established in 2014, the company maintains its headquarters in Taichung City, Taiwan.

Key people

Chung-Cheng Liu
Chairman of the Board · since 2019
Hongdun Chen
Finance Manager · since 2019
Zhewei Zhang
General Manager · since 2019
Simon Kao
Deputy General Manager of Business-General Manager's Office · since 2015
Director · since 2019
Director · since 2019
Director · since 2014
IPO date
Sep 18, 2018
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT